aTYR PHARMA INC Finance Lease, Liability, to be Paid, Year Five
aTYR PHARMA INC (ATYR) had Finance Lease, Liability, to be Paid, Year Five of $33.00 thousand as of 2022-12-31, per its 10-K filed 2023-03-14.
Discontinued › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive · last filed 2023-03-14
- 2022-12-31: Finance Lease, Liability, to be Paid, Year Five $33.00K.
| Period end | Finance Lease, Liability, to be Paid, Year Five |
|---|---|
| 2022-12-31 | $33.00K 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |